It’s National Assisted Living Week, and McKnight’s Senior Living is celebrating with a panel discussion on Wednesday and a podcast on Thursday. Here’s what you’ll want to know about those events.
New drug for Alzheimer’s disease shows promise in phase 3 trial
Sep 28, 2022
Lecanemab is a monoclonal antibody drug designed to target and help remove Alzheimer’s-associated amyloid plaques in the brain.
AI ‘promising’ for use in geriatrics, but ethical concerns remain, researchers say
By
Aaron Dorman
Sep 22, 2023
A new meta-study on using AI within geriatrics praises AI as a “valuable asset” but still warns about the need for future research and potential ethical concerns.
US life expectancy drops for second year thanks to COVID-19, drug overdoses: CDC
By
Kimberly Bonvissuto
Jan 03, 2023
Life expectancy in the United States fell for a second consecutive year due to COVID-19 deaths and drug overdoses, falling to the shortest lifespan since 1996, according to a recent report from the Centers...
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.
Smorgasbord of health tech innovations presented in Finland; country’s senior centers reaping benefits
By
Aaron Dorman
Aug 03, 2023
Many emerging healthcare technologies aimed at seniors were on display at Finland’s recent Radical Health Festival.
1 in 10 older adults have dementia, and that’s going to grow with aging population boom
By
Kimberly Bonvissuto
Oct 25, 2022
The first nationally representative study of cognitive impairment and dementia in more than 20 years found nearly one in 10 US older adults has dementia, and 22% have mild cognitive impairment.
Memory care’s dynamics make it an attractive senior housing investment prospect: NIC
By
Kimberly Bonvissuto
Jun 20, 2023
Increasing demand, combined with notable pandemic recovery, make memory care an attractive prospect for investors, but senior housing stakeholders looking to capitalize on the trend need to understand...
FDA approves first drug meant to ease Alzheimer’s disease-llnked agitation
May 11, 2023
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo.
A big lump of coal … and an opportunity
By
Lois A. Bowers
Dec 18, 2023
Christmas came early for the senior living field on Sunday, when providers collectively found a big lump of coal in the industry stocking. But that stocking also contains an opportunity.